Interstitielle Lungenbeteiligung bei der rheumatoiden Arthritis

Philipp Klemm; Jörg Henes; Panagiota Xanthouli

doi:10.1055/a-1893-4857

Arthritis und Rheuma, Table of Contents

Arthritis und Rheuma 2022; 42(05): 324-329
DOI: 10.1055/a-1893-4857

Schwerpunkt

Interstitielle Lungenbeteiligung bei der rheumatoiden Arthritis

Interstitial lung disease in rheumatoid arthritis

Philipp Klemm

¹Justus-Liebig University Gießen, Campus Kerckhoff, Abteilung für Rheumatologie, klinische Immunologie, Osteologie und Physikalische Medizin, Bad Nauheim

,

Jörg Henes

²Zentrum für Interdisziplinäre Klinische Immunologie, Rheumatologie und Autoimmunerkrankungen und Abteilung II des Departments für Innere Medizin, Universitätsklinikum Tübingen, Tübingen

,

Panagiota Xanthouli

³Sektion für Pulmonale Hypertonie, Thoraxklinik am Universitätsklinikum Heidelberg; Innere Medizin V Hämatologie/Onkologie/Rheumatologie, Universitätsklinikum Heidelberg

› Author Affiliations

Abstract

ZUSAMMENFASSUNG

Die RA-ILD ist eine schwerwiegende extraartikuläre Manifestation der RA, welche mit einer gesteigerten Mortalität einhergeht. Dieser Beitrag verschafft einen Überblick und greift neue Erkenntnisse zu diesem wichtigen Thema auf. Eingegangen wird auf Epidemiologie, Risikofaktoren, Prognose sowie auf Diagnostik und Therapie. Besonders wichtig sind die frühe Diagnose und die Evaluation der Risikofaktoren. Diese ermöglichen eine Prognoseabschätzung. Dabei spielt die HRCT-Morphologie der Lungen wie auch eine Mutation in MUC5B eine besondere Rolle. In der täglichen Praxis sollte Augenmerk auf Anamnese, körperliche Untersuchung und die regelmäßige Lungenfunktion gerichtet werden, um progredient fibrosierende Verläufe der RA-ILD frühzeitig zu entdecken. Für diese Verlaufsformen gibt es neben der Therapie mittlerweile auch die Option einer antifibrotischen Therapie.

ABSTRACT

RA-ILD is an important extra-articular manifestation of RA and associated with increased mortality. This article provides an overview and reviews recent findings. Epidemiology, risk factors, prognosis as well as diagnostics and therapy are addressed. Early diagnosis and evaluation of risk factors are particularly important. These allow prognosis estimation. Attention should be paid to HRCT morphology of the lungs and to mutation in MUC5B. In daily practice patient history, physical examination and regular pulmonary function testing to detect progressive fibrosing courses of RA-ILD early on are crucial. For progressive fibrosing RA-ILD, there is now the option of antifibrotic therapy in addition to immunomodulatory therapy.

Schlüsselwörter

Rheumatoide Arthritis - Lunge - Lungenfibrose - Therapie

Keywords

Rheumatoid arthritis - lung - fibrosis - therapy

Full Text

References

Literatur
1 Alunno A, Gerli R, Giacomelli R, Carubbi F. Clinical, Epidemiological, and Histopathological Features of Respiratory Involvement in Rheumatoid Arthritis. BioMed Research International 2017: 2017
2 Spagnolo P, Lee JS, Sverzellati N. et al The Lung in Rheumatoid Arthritis. Arthritis & Rheumatology 2018; 70: 1544-1554
3 Raimundo K, Solomon JJ, Olson AL. et al Rheumatoid Arthritis – Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality. The Journal of Rheumatology 2019; 46: 360-369
4 Hyldgaard C, Hilberg O, Pedersen AB. et al A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 2017; 76: 1700-1706
5 Joshua V, Hensvold AH, Reynisdottir G. et al Association between number and type of different ACPA fine specificities with lung abnormalities in early, untreated rheumatoid arthritis. RMD Open 2020; 06: e001278
6 Chen J, Shi Y, Wang X. et al Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. Clinical and Developmental Immunology 2013: 2013
7 Doyle TJ, Patel AS, Hatabu H. et al Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. American Journal of Respiratory and Critical Care Medicine 2015; 191: 1403-1412 10.1164/RCCM.201411-1950OC/SUPPL_FILE/DISCLOSURES.PDF
8 Kelly CA, Saravanan V, Nisar M. et al Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics – a large multicentre UK study. Rheumatology (Oxford) 2014; 53: 1676-1682
9 McDermott GC, Doyle TJ, Sparks JA. Interstitial lung disease throughout the rheumatoid arthritis disease course. Curr Opin Rheumatol 2021; 33: 284
10 Juge P-A, Lee JS, Ebstein E. et al MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. N Engl J Med 2018; 379: 2209-2219
11 Kelly C, Iqbal K, Iman-Gutierrez L. et al Lung involvement in inflammatory rheumatic diseases. Best Practice & Research Clinical Rheumatology 2016; 30: 870-888
12 Yunt ZX, Chung JH, Hobbs S. et al High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival. Respiratory Medicine 2017; 126: 100-104
13 McDermott G, Gill R, Gagne S. et al Associations of the MUC5B Promoter Variant with Timing of Interstitial Lung Disease and Rheumatoid Arthritis Onset. Rheumatology (Oxford) 2022
14 Juge P, Granger B, Debray M. et al A Risk Score to Detect Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis Rheumatol 2022
15 Nieto MA, Rodriguez-Nieto MJ, Sanchez-Pernaute O. et al Mortality rate in rheumatoid arthritis-related interstitial lung disease: the role of radiographic patterns. BMC Pulmonary Medicine 2021; 21: 1-9
16 Solomon JJ, Chung JH, Cosgrove GP. et al Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. European Respiratory Journal 2016; 47: 588-596
17 Nagy G, Roodenrijs NM, Welsing PM. et al EULAR definition of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases 2020:annrheumdis-2020–217344
18 Cottin V, Hirani NA, Hotchkin DL. et al Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. European Respiratory Review 2018: 27
19 Olson A, Hartmann N, Patnaik P. et al Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey. Advances in Therapy 2021; 38: 854
20 Krause A, Rubbert-Roth A. Pulmonary involvement in rheumatoid arthritis. Zeitschrift für Rheumatologie 2019; 78: 228-235
21 Bluett J, Jani M, Symmons DPM. Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis. Rheumatology and Therapy 2017; 04: 309
22 Keyßer G. Methotrexat-Toxizität. Zeitschrift für Rheumatologie 2011; 70: 108-113
23 Conway R, Low C, Coughlan RJ. et al Methotrexate and lung disease in rheumatoid arthritis: A meta-analysis of randomized controlled trials. Arthritis and Rheumatology 2014; 66: 803-812
24 Ridker PM, Everett BM, Pradhan A. et al Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. New England Journal of Medicine 2019; 380: 752-762 10.1056/NEJMOA1809798/SUPPL_FILE/NEJMOA1809798_DATA-SHARING.PDF
25 Sparks JA, Dellaripa PF, Glynn RJ. et al Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial. Arthritis & Rheumatology 2020; 72: 2065-2071
26 Juge P-A, Lee JS, Lau J. et al Methotrexate and rheumatoid arthritis associated interstitial lung disease. European Respiratory Journal 2021; 57: 2000337
27 Kiely P, Busby AD, Nikiphorou E. et al Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open 2019; 09: e028466
28 Rojas-Serrano J, Herrera-Bringas D, Pérez-Román DI. et al Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. Clinical Rheumatology 2017; 36: 1493-1500
29 Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med 2011; 17: 362-367
30 Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C. et al Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011; 41: 256-264
31 Curtis JR, Sarsour K, Napalkov P. et al Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor aα agents, a retrospective cohort study. Arthritis Research and Therapy 2015; 17: 1-13
32 Otsuji N, Sugiyama K, Arifuku H. et al Effect of tocilizumab on interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA). European Respiratory Journal 2020; 56: 747
33 Manfredi A, Cassone G, Furini F. et al Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Intern Med J 2020; 50: 1085-1090
34 Fernández-Díaz C, Loricera J. et al Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. Seminars in Arthritis and Rheumatism 2018; 48: 22-27
35 Fernández-Díaz C, Castañeda S, Garcia-Magallon B. et al THU0186 Rheumatoid arthritis and interstitial lung disease. multicentric retrospective study of 118 patients treated with biological no anti tnf. Annals of the Rheumatic Diseases 2018; 77: 312-312
36 Fernández-Díaz C, Atienza-Mateo BDS, Castañeda S. et al Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis – multicentre study of 263 Caucasian patients. Rheumatology 2021; 61: 299-308
37 Fui A, Bergantini L, Selvi E. et al Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis. Intern Med J 2020; 50: 330-336
38 Vadillo C, Nieto MA, Romero-Bueno F. et al Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry. Rheumatology (Oxford) 2020; 59: 2099-2108
39 Sra S, Myall K, Lams B. et al The effect of Rituximab treatment on progression of Rheumatoid arthritis-associated interstitial lung disease. European Respiratory Journal 2018; 52: OA3821
40 Md Yusof MY, Kabia A, Darby M. et al Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years’ experience at a single centre. Rheumatology 2017; 56: 1348-1357
41 Montero P, Milara J, Roger I, Cortijo J. Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms. Int J Mol Sci 2021: 22
42 Cronin O, McKnight O, Keir L. et al A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease. Rheumatol Int 2021; 41: 921-928
43 Tardella M, di Carlo M, Carotti M. et al A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease. Inflammopharmacology 2022; 30: 705-712
44 Flaherty KR, Wells AU, Cottin V. et al Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New England Journal of Medicine 2019; 381: 1718-1727
45 Wells AU, Flaherty KR, Brown KK. et al Nintedanib in patients with progressive fibrosing interstitial lung diseases – subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. The Lancet Respiratory Medicine 2020; 08: 453-460
46 Matteson EL, Kelly C, Distler JHW. et al Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial. Arthritis & Rheumatology 2022; 74: 1039-1047